Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight ...
Glucagon-like peptide agonists, or GLP-1, are seen by many as miracle drugs based on dramatic weight loss.
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
A new study found that a combination of hormone therapy and the GLP-1 medication tirzepatide (Zepbound) led to 35% more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results